Australian researchers have identified a surprising new finding for CD4 helper T cells in people with coeliac disease.
New Australian research has revealed a small but important difference in how immune cells function in people with coeliac disease.
The study, published in Immunology & Cell Biology, aimed to explore how genetic risk for autoimmune conditions potentially translated into differences in how T cells function between people with and without coeliac disease.
“Understanding these early defects could lead to better ways to predict risk, monitor disease, and eventually develop treatments that restore healthy immune balance, not just manage symptoms through a gluten‑free diet,” said senior author Dr Vanessa Bryant (PhD), deputy scientific director of the Snow Centre for Immune Health.
The research team were specifically interested in CD4 helper T cells, and how well these cells read and store activation signals to maintain activity after the original stimulus has been removed.
They hypothesised that cells from people with coeliac disease would be more active than cells from people without, given coeliac is an autoimmune condition characterised by an acquired and adaptive immune system response to gluten.
But instead of the CD4 helper T cells from people with coeliac disease being more active than in people without the autoimmune condition, they displayed a lower level of activity. Specifically, the CD4 helper T cells produced a smaller amount of interleukin-2 (a key immune signalling molecule), progressed to cell division more slowly, and were less likely to survive.
“These differences were subtle but remarkably consistent,” said Dr Bryant. “This tells us the effect simply isn’t driven by inflammation or diet… it suggests an underlying difference that may be linked to genetic risk.”
Professor Jason Dye-Tin, director of the Snow Centre for Immune Health and author of the new research, said the findings underscore the key role of cells that regulate and sustain immune responses without directly damaging tissues.
Related
“Although these helper cells aren’t always the main focus in autoimmune research, they may hold important clues to why disease develops in some people and not others,” he told media.
The researchers will now look to determine if, and at what stage, similar immune patterns occur in other autoimmune conditions.
“If autoimmune risk is partly built into how immune cells behave from the start, this could change how we think about early detection,” said Dr Bryant.
“Our long‑term goal is to understand autoimmune risk well enough that we can act earlier – potentially even before disease begins,” said Professor Tye-Din.
